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Abstract
Introduction: To establish risk factors for onset and progression of endometrioid
endometrial cancer still remains the aim of scientists. The aim of the study was
to determine disease-free survival (DFS) and overall survival (OS) in women with
endometrioid endometrial cancer. 
Material and methods: A retrospective review of 142 patients with endometrioid
endometrial cancer after surgery treated with adjuvant radiotherapy and/or
chemotherapy in the Regional Cancer Centre in Lodz between 2002 and 2004
was performed. Clinical and pathological data were correlated with clinical
outcome and survival. 
Results: In 3 patients (2.1%) clinical progression was diagnosed during the
treatment. In 23 patients (16.7%) after primary remission, relapse was diagnosed
2-56 months after treatment. DFS and OS were 81.7% and 83.1% respectively.
Better DFS significantly correlated with larger number of pregnancies (> 1), stage
I of the disease and optimal surgery. Lower stage of disease, pelvic lymph node
dissection, optimal surgery and depth of myometrial infiltration ≤ 50% were
independent prognostic factors for better OS. 
Conclusions: The results of our study provided significant evidence that early
detection of endometrioid endometrial cancer enables optimal surgery. It reduces
the indications for adjuvant therapy in stage I of the disease, and makes the
prognosis significantly better. Other clinical and pathological factors such as
numerous pregnancies, pelvic lymphadenectomy, and depth of myometrial
infiltration, although important, are of less significance. Further prospective,
randomized studies are necessary to prove the role of these factors.  
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Introduction
Endometrial cancer is the most common
gynaecological cancer, with an increasing incidence
rate [1-3]. In the Polish female population endometrial
cancer is ranked fourth in statistics of incidence of
cancer, and eighth in terms of age-adjusted mortality
[2]. In the United States the lifetime risk of
endometrial cancer development is evaluated at
2.7% [3]. The increased incidence of endometrial
cancer is likely to result from several factors including
prolonged average human lifespan, high-caloric
nutrition, improved health care system and living
conditions [1]. Modern diagnostic methods, advances
in surgical technique and high-efficacy adjuvant
therapy, and increased health consciousness among
women have resulted in relatively early detection of
endometrial cancer (70-80% stage I), which gives
patients better prognosis [4-7]. 
Two types of endometrial cancer are
distinguished in terms of clinical and pathological
features. Type I (endometrioid carcinoma) is asso  -
ciated with hyperoestrogenism and endometrial
hyperplasia (80-90%). Type II (non-endometrioid
carcinoma) is an oestrogen-independent malig  -
nancy, usually developing from atrophic endometrial
tissues (10-20%) [2, 3, 8]. Endometrioid carcinoma
usually occurs in younger women, often obese or
diabetic. Non-endometrioid carcinomas such as
serous papillary, clear cell, squamous cell or
undifferentiated type in most cases affect elderly
women who are neither obese nor diabetic [2, 9].
Several studies suggested more aggressive course
and worse prognosis even in early stages of non-
endometrioid endometrial cancer [2, 8-11]. The 
5-year overall survival rate (OS) of endometrioid
endometrial cancer patients ranges from 75% to
86%. In contrast, only 35% of patients with non-
endometrioid endometrial cancer survive 5 years
from diagnosis [3, 9, 10, 12].
Several risk factors of endometrioid endometrial
cancer have been identified, but the aetiology of the
disease still remains unclear. However, progression
from the pre-malignant form of intraendometrial
neoplasia to endometrioid carcinoma seems to be
well documented [1, 2, 12, 13]. To establish the risk
factors of onset and progression of this disease still
remains the aim of scientists. It may lead to more
effective treatment in patients from the subgroup
at high risk of failure and reduce the risk of over-
treatment in the low-risk group.
The aim of the study was to determine
prognostic factors for OS and disease-free survival
(DFS) in women with endometrial cancer of
endometrioid type.
Material and methods
Our study enrolled 142 consecutive endometrioid
endometrial cancer patients with median age 60.2
years (range 41-82 years), treated in the Regional
Cancer Centre in Lodz between 2002 and 2004.
Patients with incomplete follow-ups were excluded.
All cancers were classified according to the new
FIGO (International Federation of Gynecology and
Obstetrics) classification 2009 [14]. Detailed clinical
and pathological characteristics of the study group
are presented in Table I.
Hundred forty one patients underwent surgical
procedures outside the Regional Cancer Centre in
Variables n = 142, n (%)
Age [years] ≤ 60 77  (54.2)
> 60  65 (45.8)
History of cancer no 109 (76.8)
patient 5 (3.5)
family 28 (19.7)
Pregnancies    yes 127 (19.4)
no 15 (10.6)
Menopausal status  premenopausal 18 (12.7)
postmenopausal 124 (87.3)
Age at menopause  ≤ 50 61  (43.0)
[years] >50 81  (57.0)
Medical illness   yes 89 (62.7)
no 53 (37.3)
Stage   I 96 (67.6)
II 18 (12.7)
III 26 (18.3)
IV 2 (1.4)
Depth of myometrial  ≤ 50% 72 (50.7)
infiltration > 50% 70 (49.3)
Grade   1 71 (50.0)
2 54 (38.0)
3 17 (12.0)
Surgery       no or explorative 2 (1.4)
cytoreductive 6 (4.5)
optimal 134 (94.1)
TAH + BSO  40 (28.1)
TAH + BSO + PL 100 (70.5)
Adjuvant treatment no 6 (4.2)
BT alone 10 (7.1)
BT + EBRT 122(85.9)
CT ± RT 4 (2.8)
Table I. Clinical and histological characteristics of the
study group
TAH – total abdominal hysterectomy, BSO – bilateral salpingo-
oophorectomy, PL – pelvic lymphadenectomy, CT – chemotherapy, 
BT – vaginal brachytherapy, EBRT – external-beam pelvic radiotherapy,
RT – radiotherapyArch Med Sci 6, December / 2010 939
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Lodz. During surgery in 140 patients uterus and
both adnexa were removed (TAH-BSO). In 99
(69.7%) cases pelvic lymphadenectomy (PL), and in
67 (47.2%) cases appendectomy were additionally
performed. Para-aortic lymph node sampling was
not performed in these cases. Intraoperative
procedures when TAH-BSO with complete resection
of all visible cancer were regarded as optimal
surgery. In one woman at stage IV no history of
surgery was noted and in one patient the only
explorative laparotomy was made. Afterwards
adjuvant treatment was conducted in the
Department of Gynaecologic Radiotherapy. Most
women received adjuvant vaginal brachytherapy
(BT) and external beam pelvic radiotherapy (EBRT).
Additionally, selected patients were treated by
chemotherapy (CT) and hormonal therapy (HT)
(Table I). Afterwards the patients attended the
Gynaecological Cancer Outpatient Clinic for follow-
up. The clinical outcome of all patients during 
5 years of observation was analysed. Personal,
obstetric, oncological, clinical and pathological data
were correlated with DFS and OS. 
The DFS was defined as the period from primary
surgery until relapse. OS was defined as the period
from primary surgery until death or until completion
of 5-year follow-up. Complete remission (CR) was
defined as the disappearance of all signs of cancer
in response to treatment. Progression of neoplastic
disease was defined as the course of the disease
as it becomes worse or spreads in the body. Relapse
of cancer was defined as the return of signs and
symptoms of cancer after a period of improvement. 
To assess survival parameters Kaplan-Meier
analysis was used [15] and survival curves were
compared using the log-rank test [16]. Statistical
analysis of survival was performed with the log-
rank test and Cox models. A p value less than 0.05
was considered significant. 
Results
Complete remission was observed in 116 out of
142 (81.7%) patients during 5 years of follow-up.
Clinical progression or relapse was diagnosed 
in 26 (18.3 %) patients. In 3 patients (2.1%) with
stage III or IV of the disease, clinical progression
during primary treatment was diagnosed. Two of
them had locoregional recurrence in the pelvis
minor and dissemination of the disease after a few
months was found. In 1 case bone and liver
metastases were observed. These 3 patients were
treated symptomatically and died during 5 months.
Relapse was observed in 23 (16.2%) patients
from 2 to 56 months (median 23.6, SD = 16.3) after
CR achievement. Twenty-one out of 23 (91.3%)
patients with relapse died after 1 to 21 months
(median 7.6) from diagnosis despite the consecutive
line of treatment, and only 2 (8.7%) patients with
recurrent disease survived 5 years (p < 0.001).
Detailed results of treatment are shown in Table II.
The DFS rate at 5 years of the entire group was
81.7%. In univariate and multivariate analyses,
larger number of pregnancies (p = 0.021, p = 0.041),
clinical stage I (p = 0.002, p = 0.04) and optimal
surgery (p = 0.01, p = 0.028) significantly influenced
DFS. In univariate and multivariate analyses, age at
diagnosis, menopausal age and menopausal status,
familial and patient cancer history, other diseases,
pelvic lymph node dissection, depth of myometrial
infiltration, grade of the tumour and type of adjuvant
treatment in clinical stage I (no adjuvant and/or only
vaginal brachytherapy [BT] vs. BT and external-beam
pelvic radiotherapy [EBRT]) did not affect DFS. These
results are summarized in Table III.
The OS rate at five years of the study group was
83.1%. In univariate analysis, clinical stage I
(p < 0.001; Fig. 2), optimal surgery (p < 0.001; Fig. 1),
pelvic lymph node dissection (p < 0.001), depth of
myometrial infiltration ≤ 50% (p < 0.001; Fig. 4), and
well or moderately differentiated tumour (p = 0.014;
Fig. 3) significantly influenced OS. Clinical stage I
(p = 0.002), optimal surgery (p = 0.006), pelvic
lymph node dissection (p = 0.015), and depth of
myometrial infiltration ≤ 50% (p = 0.02) were
independent prognostic factors for OS in
Location of relapse
only locoregional 3 13
only distant metastatic 15 65.2
both locoregional and distant 5 21.8
total 23 100.0
Location of distant relapses at diagnosis
liver 7 30.4
lungs 7 30.4
bones 3 13.0
para-aortic and/or extraperitoneal  6 26.1
lymph nodes
abdominopelvic layer 3 13.0
central nervous system 2 8.7
supraclavicular lymph nodes 1 4.3
Treatment of relapses
only CT 6 26.1
S + CT 2 8.7
only EBRT 2 8.7
BT + EBRT 1 4.3
HT and symptomatically 1 4.3
only symptomatically 11 47.9
Table II. Relapse of the disease
S – surgery, CT – chemotherapy, BT – vaginal brachytherapy, 
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multivariate analysis. In univariate and multivariate
analyses, age at diagnosis, larger number of
pregnancies, menopausal age and menopausal
status, familial and patient cancer history, con  -
comitant diseases, and type of adjuvant treatment
in clinical stage I (no adjuvant or only BT vs. BT 
and EBRT) were not significantly related to OS
(Table III). 
Patients DFS OS
n % p1 p2 n % p1 p2
TOTAL 116 / 142 81.7 – – 118 / 142 83.1 –
Age* [years] ≤ 60  64 / 77 85.7 0.61 0.64 65 / 77 84.4 0.35 0.28
> 60  52 / 65 80.0 53 / 65 81.5
History  no 91 / 109 83.5 0.77 0.11 92 / 109 83.8 0.38 0.13
of cancer 
patient 3/5 60.0 3/5 60.0
family 23 / 28 82.1 24 / 28 85.7
Pregnancies* yes 104 / 127 81.9 0.021 0.041 106 / 127 83.5 0.13 0.09
no 12 / 15 80.0 12 / 15 80.0
Menopausal  premenopausal 17 / 18 94.4 0.41 0.90 17 / 18 94.4 0.16 0.73
status
postmenopausal 99 / 124 79.8 101 / 124 81.5
Age at  ≤ 50  47 / 61 77.0 0.43 0.09 49 / 61 80.3 0.25 0.58
menopause*
> 50  69 / 81 85.2 69 / 81 85.2
Medical  yes 75 / 89 84.3 0.31 0.95 76 / 89 85.4 0.46 0.67
illness
no 41 / 53 77.4 42 / 53 79.2
Stage   I 90 / 96 93.8 0.002 0.040 91 / 96 94.8 < 0.001 0.002
II 13 / 18 72.2 13 / 18 72.2
III 13 / 26 50.0 14 / 26 53.8
IV 0 / 2 0 0 / 2 0
Myometrial  ≤ 50% 69 / 72 95.8 0.09 0.38 69 / 72 95.8 < 0.001 0.02
infiltration
> 50% 47 / 70 67.1 49 / 70 70.0
Grade   1 62 / 71 87.3 0.29 0.70 63 / 71 88.7 0.014 0.09
2 43 / 53 81.1 44 / 53 83.0
3 11 / 18 61.1 11 / 18 61.1
Surgery no or explorative 0 / 2 0 0.01 0.028 0 / 2 0 < 0.001 0.006
cytoreductive 0 / 6 0 0 / 6 0
optimal 116 / 134 86.6 118 / 134 88.1
TAH + BSO  28 / 40 70.0 0.13 0.24 29 / 40 72.5 < 0.001 0.015
TAH + BSO + PL  88 / 100 88.0 89 / 100 89.0
Adjuvant  no 5 / 6 83.3 < 0.001 0.049 5 / 6 83.3 0.67 0.35
treatment BT alone 8 / 10 80.0 8 / 10 80.0
BT + EBRT 103 / 122 84.4 105 / 122 86.1
CT +/– RT 0 / 4 0 0 / 4 0
FIGO I ** 0.23 0.37 FIGO I ** 0.11 0.07
FIGO II-III *** – – FIGO II-III *** – –
FIGO IV – – FIGO IV – –
p1 – univariate analysis, p2 – multivariate analysis, TAH – total abdominal hysterectomy, BSO – bilateral salpingo-oophorectomy, PL – pelvic
lymphadenectomy, CT – chemotherapy, BT – vaginal brachytherapy, EBRT – external-beam pelvic radiotherapy, RT – radiotherapy, * in statistical
analysis the exact values of all parameters in all patients were taken into account, ** no adjuvant treatment or only BT vs. BT + EBRT, *** the
treatment in these patients was BT + EBRT
Table III. Disease-free survival (DFS) and 5-year overall survival (OS) – univariate and multivariate analysis 
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Discussion
In our study DFS and OS rates at five years were
similar to data published by Hirai et al. [13], and
were 81.7% and 83.1% respectively. In the last years
there have been published numerous studies
addressing the effects of different independent
variables on the risk of development and prognosis
of endometrioid endometrial cancer [1, 4-6, 11, 13,
17-23]. Age at diagnosis, age at menarche, parity,
menopausal age, menstrual status, hormonal
contraception, and hormone replacement therapy
are well known risk factors for developing the
cancer [2, 3, 11, 13, 17, 18], but as in our study, their
role as prognostic factors predicting survival
remains controversial. Only higher number of
pregnancies was correlated with better DFS, and
our results match well with those of Alkbretsen et
al. [19] reporting the relationship between obstetric
history and prognosis in endometrioid endometrial
cancer patients. They found better survival in
parous than nulliparous women, and in the study
the improved effect was strongest for women with
the shortest time interval since the last childbirth.
This interesting pattern may be a consequence of
high progesterone levels, and interruption of the
continued stimulation from oestrogen during
pregnancy [3].
0 365 730 1095 1460 1825
time [days]
Figure 1. OS and radicality of surgery in endometrioid
endometrial cancer.
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Figure 2. OS and staging of endometrioid endome  -
trial cancer.
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Figure 3. OS and grading of endometrioid endome  -
trial cancer.
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Figure 4. OS and myometrial infiltration in endome  -
trioid endometrial cancer.
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When planning the treatment of endometrioid
endometrial cancer, complete pathological and
clinical data predicting the course of the disease
should be taken into consideration. It is generally
known and confirmed in our results that the most
important factor affecting survival is clinical stage
[12, 13, 24, 25], which determines the mode of
treatment, significantly predicting DFS and OS. As
an example, Hirai et al. [13] in 286 patients reported
the overall 5-year recurrence-free survival in stage
I – 94%, stage II – 71% and stage III – 38%. 
The treatment of choice in operable endometrial
cancer is surgery including minimally: TAH-BSO,
sampling of peritoneal fluid and resection of all
visible extra-uterine metastatic lesions, followed by
adjuvant treatment [12, 26]. Previous studies
showed that dissection of pelvic and para-aortal
lymph nodes in all patients with endometrioid
endometrial cancer remains controversial, because
this procedure did not influence survival in clinical
stage I [4, 12]. Ayhan et al. suggest instead
performing pelvic lymphadenectomy in all patients
because the most important prognostic factor in
endometrial cancer is nodal involvement. Results
of pelvic lymphadenectomy best determine the
exact stage of patients, and allow tailoring of
adjuvant therapy, and pelvic lymphadenectomy
itself provides survival benefit and does not
increase morbidity significantly [21]. In our study
pelvic lymph node dissection correlated with longer
OS in the whole group of patients as well. We
conclude that, when technically feasible, pelvic
lymph node dissection should be recommended in
stage I-III disease. According to para-aortic
lymphadenectomy, many authors have described
para-aortic node biopsy as a non-therapeutic
procedure [27], but Mariani et al. postulated its
possible therapeutic role based on a selected group
of 137 high-risk patients with endometrial cancer
[28]. As para-aortic lymph node dissection is not
routinely performed in all centres of gynaecological
oncology, and this procedure is noted as technically
demanding surgery, in our material it was not
performed even in high-risk patients.
Although many studies have reported
a significant negative correlation between grade of
tumour and outcome [8, 9, 29], our findings match
well with those of Zaino et al. [30] and
demonstrated tumour grade to be a less significant
predictor of survival, with myometrial infiltration
more important [24]. The results do not match well
with those of Ayhan et al. [4], who in a group of 48
patients with endometrioid endometrial cancer in
clinical stage II found high grade (G3) of the tumour
to be a significant predictor of poor survival, and
depth of myometrial infiltration was not related
significantly to either DFS or OS. Interestingly, in
the Gynecologic Oncology Group (GOG) study on
895 cases of endometrioid and adenosquamous
carcinoma by Marrow et al., both depth of
myometrial infiltration more than one-third and
tumour grade 3 were demonstrated to be strong
predictors of prognosis, extra-uterine disease and
distant relapses in patients with stage I or II
endometrial cancer [24]. Cirisano et al. [10] assessed
the risk of positive pelvic nodes from 1% for
tumours confined to the endometrium up to 25%
for those with deep (> 50%) myometrial infiltration.
In our opinion the need of adjuvant treatment
should be based on risk of relapse determined not
only by stage, grade of tumour, and lymph vascular
space involvement (LVSI), but in patients staged
I additionally depth of myometrial infiltration as
well.
Despite endometrial carcinoma being the most
common gynaecological cancer in Poland,
controversy exists regarding the indications for
adjuvant radiotherapy, especially in clinical stage I
[31]. Using surgical staging data according to the
GOG [24] and the new FIGO classification from 2009
[14], in low-risk (IA G 1-2) endometrioid endometrial
cancer adjuvant treatment is not necessary,
because of the low recurrence rate calculated as 
1-5% [5, 21, 22, 26]. Our results match well with the
above cited recommendations, showing that
radiotherapy did not improve DFS or OS in stage
I disease. We also confirmed a positive correlation
of adjuvant radiotherapy administered to patients
with clinical stage II-III disease with DFS and OS.
This matches well with the GOG recommendation
[24] that when intermediate-risk (stage IA G 3, stage
IB/2 G 1-3) or high-risk (stage III) endometrioid
endometrial cancer is diagnosed, with calculated
risk for relapse 10% and 14-42% respectively [5, 20,
26], adjuvant therapy is recommended [4, 5, 20, 25,
31, 32]. The National Comprehensive Cancer
Network (NCCN) Practice Guidelines [33]
recommend vaginal brachytherapy (BT) and/or
external-beam pelvic radiotherapy (EBRT) in
intermediate-risk endometrial cancer patients, and
BT and/or chemotherapy (CT) in patients with FIGO
IB G3 and unfavourable risk factors (age > 60 years,
positive LVSI, tumour size, lower uterine
involvement) and II G3. Additionally, EBRT and/or
CT is widely used as an adjuvant for intermediate-
risk endometrial cancer, giving about 10% survival
improvement, high locoregional control rates and
acceptable toxicity. Although in the GOG122 trial
[34] a superior effect on DFS of chemotherapy
compared to whole abdominal irradiation for high-
risk patients in stage III or IV with abdominal
disease and residual nodules ≤ 2 cm was confirmed,
different treatment schemes (EBRT and/or CT) in
these patients are used worldwide [12,13]. Recurrent
or metastatic endometrial tumours often respond
to salvage treatment with cytotoxic agents, andArch Med Sci 6, December / 2010 943
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nowadays systemic CAP (cisplatin-adriablastin-
endoxane) therapy as a post-surgical adjuvant
treatment for high-risk endometrial cancer patients
instead of radiotherapy is often used [35]. In our
centre during 2002-2004 systemic CAP therapy was
used mainly in relapses, and only in selected cases
as primary adjuvant treatment. 
Although the majority of patients with
endometrial cancer are diagnosed with no evidence
of extra-uterine spread [6], even in low-risk patients
local relapses may develop. In our study, cancer
progression during treatment or relapse occurred
in 18.3% of patients. Local recurrences of
endometrial cancer, similarly to cervical cancer,
often occur early with evident symptoms but
development of distant metastatic disease may
cause difficulties in prompt diagnosis [23, 26, 36].
The previous study showed that in these patients
survival rate is thought to be related to site of
relapse as the most important factor, but also
disease-free interval, and postoperative treatment
as independent prognostic variables [23, 26]. The
response rates to systemic therapy reported in the
literature in the range 10-78% are generally better
than in our study, but this may be due to
differences in the studied patient populations [6,
7]. The results of further treatment in our patients
were similar to data published by Carey et al. [7],
who found that median survival in patients with
advanced endometrial cancer or distant recurrent
disease rarely exceeds 1 year, despite systemic
therapy. 
Finally, the primary goal of a surveillance strategy
in patients who have been treated for endometrial
cancer is to facilitate the early detection of recurrent
disease, but even in such cases the prognosis for
patients should be assessed very carefully.
The results of our study provided significant
evidence that early detection of endometrioid
endometrial cancer enables optimal surgery. It
reduces the indications for adjuvant therapy in
stage I of the disease, and makes the prognosis
significantly better. Other clinical and pathological
factors such as numerous pregnancies, pelvic
lymphadenectomy, and depth of myometrial
infiltration, although important, are less significant.
Further prospective, randomized studies are
necessary to clarify the role of these factors.  
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